• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Novo Nordisk's AM833 shows early success in obesity trials pharmatimes
    June 22, 2020
    Novo Nordisk has unveiled headline results from two clinical trials with a novel once-weekly subcutaneous amylin analogue (AM833) - a Phase II monotherapy trial and a Phase I combination trial of AM833 and once-weekly subcutaneous semaglutide.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service